title: Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014.
abstract: We have studied the pharmacokinetics and the effects of BIM 23,014 (BIM), a new, long-acting octapeptide somatostatin analogue, on basal and stimulated GH secretion in normal men. BIM 250 micrograms sc significantly reduced a GHRH-induced increase in plasma GH. The continuous sc administration of BIM for 24 h dramatically blunted spontaneous GH secretion; 2000 and 3000 micrograms daily reduced GH secretion to a greater extent than 1000 micrograms daily. During these experiments a significant negative correlation (r - 0.66) was found between plasma GH and BIM levels. Acute sc administration of 1000 micrograms BIM significantly reduced the rise in plasma GH observed in the second part of the oral glucose tolerance test. Plasma BIM levels peaked around 30 min, and the elimination half life was 90 min. Plasma BIM levels were below 1 ng/ml 6 h after the injection of 1000 micrograms BIM, and at that time GH started to rise again. We conclude that BIM 23,014 250 to 1000 micrograms sc is able to reduce the plasma GH response to GHRH or to the fall in glucose following an oral glucose tolerance test; a constant infusion of BIM, in doses 1000 micrograms daily, dramatically suppresses spontaneous GH secretion; 2000 micrograms/day by chronic subcutaneous infusion was the most effective dose of BIM in the suppression of GH secretion, and was associated only with minor adverse effects.
authors.affiliation: Department of Endocrinology, Hôpital de Bois Buillaume, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Kuhn
authors.forename: C
authors.initials: C
authors.lastname: Basin
authors.forename: M
authors.initials: M
authors.lastname: Mollard
authors.forename: B
authors.initials: B
authors.lastname: de Rougé
authors.forename: C
authors.initials: C
authors.lastname: Baudoin
authors.forename: R
authors.initials: R
authors.lastname: Obach
authors.forename: G
authors.initials: G
authors.lastname: Tolis
mesh_terms: D000328:Adult; D013006:Growth Hormone / Q000097:blood / Q000187:drug effects* / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D010456:Peptides, Cyclic / Q000493:pharmacokinetics / Q000494:pharmacology*; D013004:Somatostatin / Q000031:analogs & derivatives*
chemical_list: D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone